Intersting thoughts

Search

Member
Joined
Dec 13, 2007
Messages
13,685
Tokens
Got to take a deep breath on SQQQ and try to stay with the persuasive though that the nasdaq is over bought in a large way.
Worst case is a reverse split..then the math gets ugly.
As far as China goes they've made the right moves with C19 the fundamentals in the Shanghai market makes more sense to me right now.
I got pushed around today in a big way with BABA Down 13 % today alone and depending on the rhetoric next week it could get worst.
I'd stress rhetoric... it's a gift if like BABA JD or Tencent long.

I'm sticking with my plan trying to say cool.
 

Member
Joined
Dec 13, 2007
Messages
13,685
Tokens
Opps not "say cool"..but "stay cool"

Pretty interesting the President held a presser at his CC yesterday and talked about an executive order on the gridlocked stimulus plan.
The gridlock is now assured to continue IMO till Trumps hand is forced on the order..It works for both parties and Trump too.
Dems can point to Trumps overreach and the Reps can point to the Dems ineptitude, Trump ends up looking like he's rescuing the People from evictions and poverty.
I just wonder what the market will feel..above all, in normal times the market dislikes uncertainty but this market baffles me.
 

Member
Joined
Apr 30, 2009
Messages
5,008
Tokens
Last 7 market days alone FSLY goes from $88 (I buy) to $118 (I put in stop market at $103). Falls to $88 after hours (I get filled at $89 lol) then $79 the next day. This is not normal lmao.
 

Member
Joined
Dec 13, 2007
Messages
13,685
Tokens
World Acceptance.
WRLD. Price...65.82
This is a shit company who got a reprieve during the Trump presidency with the abandonment of many regulations against short term lenders (predatory)
Analysts hate it, I think it's worth watching.



WRLD..83.63 Sold the rest.
I don't trust this company and don't like holding it long.. if it dips I'll be back again.
Always has very strange volume but manages upward movement. Analysts still hate it.

 

Member
Joined
Dec 13, 2007
Messages
13,685
Tokens
[FONT=Roboto, sans-serif]Great call this AM..Top line numbers have been a key in previous JAZZ take outs.
JAZZ stock up big over the last 10 days.
[/FONT]



  • [*=left]Presented positive topline data from the pivotal Phase 3 REST-ON study
  • Announced today that results of the data analyses for the secondary endpoints of the REST-ON study were consistent with the primary analyses and further demonstrated the overall statistical significance of FT218 compared to placebo
  • Completed the pre-NDA meeting for FT218 with the Food and Drug Administration
  • First patient dosed in the open-label extension/switch study of investigational once-nightly FT218
  • Strengthened balance sheet through completion of $125 million public equity offering to support the company’s strategic priorities
  • Completed sale of the sterile injectable drug portfolio for $42.0 million
  • Management to host a conference call today at 8:30 a.m. ET
DUBLIN, Ireland, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced its financial results for the second quarter ended June 30, 2020 and provided a company update.

“We are at a pivotal point in Avadel’s transformation, as we recently completed our pre-NDA meeting with the FDA and are currently focused on completing our NDA submission and filing for FT218. A key component of the planned NDA for FT218 is the positive data from the Phase 3 REST-ON study of FT218, which was first announced in April. These data show that the three dose levels of FT218 that were tested demonstrated statistically significant (p<0.001) and clinically meaningful improvement for all three co-primary endpoints. In addition, FT218 was highly significant for the secondary endpoints that tested additional measures of daytime sleepiness, sleep architecture, and other narcolepsy symptoms compared to placebo at all three doses and all sensitivity analyses of the primary endpoint. If approved, FT218 could be the first once-nightly therapy to address both excessive daytime sleepiness and cataplexy in patients with narcolepsy,” said
Greg Divis, Chief Executive Officer of Avadel.“In May, we strengthened our balance sheet with the completion of a public equity offering for gross proceeds of $125.0 million that will be used to support the development and plan for the go-to-market strategy of FT218. In June, we further bolstered our cash position with the sale of our legacy portfolio of sterile injectable drugs for $42.0 million. Divesting this product portfolio is in line with our overall strategy to focus the Company’s resources on FT218, thus streamlining and focusing Avadel while enabling the company to maintain optionality for creating shareholder value.”

“As we move forward for the balance of 2020, our highest priority remains the completion and filing of our once-nightly FT218 NDA. In addition, we are in the process of compiling additional supporting scientific data to position FT218 in the market which includes the ongoing open-label extension (OLE)/switch study of FT218,” concluded
Mr. Divis.Second quarter and recent company highlights

  • Presented an update on the development of FT218 and positive results from the Phase 3 Rest-On clinical trial for excessive daytime sleepiness and cataplexy in patients with narcolepsy, which were previously announced in April 2020:
° FT218 at the 9 g dose demonstrated highly statistically significant (p<0.001) and clinically meaningful improvement across all three co-primary endpoints (Maintenance of Wakefulness Test, Clinical Global Impression-Improvement and Mean Weekly Cataplexy Attacks) compared to placebo.
° FT218 at the 9 g dose was generally well-tolerated, with commonly known sodium oxybate adverse reactions occurring at low rates (nausea 1.3%, vomiting 5.2%, decreased appetite 2.6%, dizziness 5.2%, somnolence 3.9%, tremor 1.3%, enuresis 9%; discontinuation rate due to adverse reactions 3.9%).
° FT218 at the 7.5 g and 6 g dose levels also achieved highly statistically significant (p<0.001), clinically meaningful improvements across all three co-primary endpoints compared to placebo, as soon as 3 weeks after initiating FT218.


  • Announced today additional data from the REST-ON study:
° All three doses of FT218 studied were highly significant compared to placebo on secondary endpoints evaluating daytime sleepiness, sleep architecture, and other narcolepsy symptoms
° FT218 was also significant compared to placebo for all sensitivity analyses of the three co-primary endpoints at all three doses
° Detailed data for the secondary endpoints and sensitivity analyses will be presented at a scientific conference or in a peer-reviewed scientific publication


  • Held a successful pre-NDA meeting with the FDA and are on track to move forward with filing our NDA for FT218
  • First patient dosed in an OLE/switch study of FT218 as a potential treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy.
  • Completed a public equity offering with gross proceeds of $125.0 million to strengthen the Company’s balance sheet and provide capital to support its strategic priorities.
  • Completed the sale of the legacy portfolio of sterile injectable drugs used in the hospital setting to Exela Sterile Medicines LLC for a total of $42.0 million.
Overview of Second Quarter Results
Revenues for the second quarter of 2020 were $10.1 million, compared to $17.6 million in the second quarter of 2019. The decline on a year-over-year basis was primarily attributed to lower overall sales volume across the Company’s hospital products as a result of increased market competition.
R&D expenses were $4.1 million in the second quarter of 2020, compared to $10.3 million in the second quarter of 2019. The decrease on a year-over-year basis was primarily attributed to the completion of the FT218 clinical study during the first quarter of 2020, as well as lower headcount due to the restructuring activities initiated during 2019.

SG&A expenses were $7.1 million in the second quarter of 2020, compared to $6.8 million in the second quarter of 2019. The year-over-year increase is primarily the result of higher professional fees and market research costs related to FT218.
A $45.8 million pre-tax gain from the sale of the portfolio of sterile injectable drugs was recorded in the second quarter of 2020. The gain reflects the $42.0 million transaction price adjusted for the net liabilities that were transferred to Exela Sterile Medicines LLC and transaction costs incurred by the company.
Income tax provision was $5.3 million in the second quarter of 2020, compared to $1.8 million in the second quarter of 2019.
Net income for the second quarter of 2020 was $30.9 million, or $0.49 per diluted share, compared to a net loss of $8.6 million, or ($0.23) per diluted share, for the same period in 2019.
Cash, cash equivalents and marketable securities were $238.6 million as of June 30, 2020. The Company has convertible debt of $143.8 million due in February 2023.
Conference Call:
A conference call to discuss these results has been scheduled for Monday, August 10, 2020 at 8:30 a.m. ET. To access the conference call, investors are invited to dial (877) 407-9716 (U.S. and Canada) or (201) 493-6779 (International). The conference ID number is 13707645. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

About FT218
FT218 is an investigational, once-nightly formulation of Micropump™ controlled-release (CR) sodium oxybate. In March of 2020, the Company completed the REST-ON study, a pivotal, double-blind, randomized, placebo-controlled Phase 3 trial, to assess the efficacy and safety of FT218 in the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. FT218 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. The designation was granted on the plausible hypothesis that FT218 may be clinically superior to the twice-nightly formulation of sodium oxybate already approved by the FDA for the same indication. In particular, FT218 may be safer due to ramifications associated with the dosing regimen of the previously approved product.

About Avadel Pharmaceuticals plc:
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Company’s primary focus is the development and potential FDA approval of FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy. For more information, please visit www.avadel.com.

Cautionary Disclosure Regarding Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects, or other events. Such forward-looking statements include, but are not limited to, the planned submission of the FT218 NDA to the FDA and commercial launch of FT218, if approved. In some cases, forward-looking statements can be identified by the use of words such as “will,” “may,” “could,” “believe,” “expect,” “look forward,” “on track,” “guidance,” “anticipate,” “estimate,” “project,” “next steps” and similar expressions, and the negatives thereof (if applicable).

Our forward-looking statements are based on estimates and assumptions that are made within the bounds of our knowledge of our business and operations and that we consider reasonable. However, our business and operations are subject to significant risks, and, as a result, there can be no assurance that actual results (including, without limitation, the continued advancement and development of FT218 and benefits and cost savings from the sale of our hospital products) and the results of our business and operations will not differ materially from the results contemplated in such forward-looking statements. Factors that could cause actual results to differ from expectations in our forward-looking statements include the risk that the impact of the current COVID-19 pandemic on our financial results and results of operations could be greater than we anticipate and the risks and uncertainties described in the “Risk Factors” section of Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, which we filed with the Securities and Exchange Commission (SEC) on March 16, 2020 and subsequent SEC filings.
Forward-looking statements speak only as of the date they are made and are not guarantees of future performance. Accordingly, you should not place undue reliance on forward-looking statements. We do not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law.
Contacts:
Investor Contacts
Tom McHugh
Chief Financial Officer
Phone: (636) 449-1843
Email: tmchugh@avadel.com

Tim McCarthy
LifeSci Advisors, LLC
Phone: (212) 915.2564
Email: tim@lifesciadvisors.com

Media Contact
Patrick Bursey
LifeSci Communications, LLC
Phone: (646) 970-4688
Email: pbursey@lifescicomms.com


 

Member
Joined
Dec 13, 2007
Messages
13,685
Tokens
I love this idea so much.. I just bought the September 260 to 285's calls.
https://finance.yahoo.com/news/mike-khouws-alibaba-trade-ahead-150001956.html


Busy morning...

Out for the day happy flipping fellas


I thought it might be helpful to offer a factual summary of President Trump’s executive actions over the weekend, because I find it very difficult to get a straightforward accounting in most parts of the press of anything that has political implications, especially as election season heats up. I will also offer a few thoughts on the economic implications.

There were 4 executive orders, corresponding to several different elements of relief that had been offered by the CARES Act that had expired or will expire.


  1. Unemployment benefits. The $600 per week bonus unemployment benefits expired July 31. Republican Congressional negotiators insisted that $600/week was too generous, as total payments for over half of workers were higher than the wages that they were replacing, in some cases by quite a lot. Democrats were similarly adamant that the economy would collapse if the bonus payments were cut by any amount.

President Trump issued an executive order to continue paying $400 per week using money that was sitting around in other accounts (the payments will be retroactive to Aug. 1). The federal government will be directly responsible for $300 per week, using money from the Disaster Relief Fund, a fund that was created by the CARES Act and has about $70 billion remaining. The extra benefits will be paid until Dec. 6 or until $44 billion of the disaster fund is exhausted, whichever comes first. To put some rough numbers on it, if the number of beneficiaries holds in the neighborhood of 25 million, then payments would total about $7.5 billion per week, and the money would only last about 6 weeks. If the number of beneficiaries falls to 15 million, closer to the Household Survey level of unemployment, the weekly payout would be about $4.5 billion per week, and the money would last 10 weeks. Either way, the benefits would be exhausted in the heat of the election season, so if there is no deal with Congress, President Trump would presumably have to go looking for a different honey pot to, at a minimum, get past Election Day.

Meanwhile, states would be responsible for a quarter of the payments, $100 per week. States can tap from the $80 billion remaining in CARES Act money available to them to make the payments, and Secretary Mnuchin indicated today that all states have more than enough money available to make the payments (and Administration officials noted that if they run out, the federal government will find a way to help). In some ways, this rubs salt in the wounds for state governments, which were hoping for hundreds of billions of dollars in new funds in the unsuccessful fiscal package and are now going to have to use a chunk of what money is left over to make these payments.


  1. Eviction Moratorium. The second executive order does not reauthorize the eviction moratorium established in the CARES Act (which expired July 31). Instead, it directs Treasury and HUD to find money to provide temporary financial assistance to renters and homeowners who can’t meet their obligations. It also directs HUD to act to “promote the ability of renters and homeowners to avoid eviction or foreclosure.” Presumably, the FHFA and Fannie and Freddie will be enlisted to help as well. This one seems awfully fuzzy, but I would assume that regulators can find ways to roughly approximate the CARES Act status quo.


  1. Payroll tax holiday. This one strikes me as the most likely to not work. Trump directed the Treasury Dept. to defer the employee half of the Social Security tax on wages for those making less than $100,000 a year. The suspension would last from Sep. 1 to Dec. 31. President Trump will ask Congress to waive these obligations altogether, but short of legislative action, the taxes are merely deferred, not expunged. So, it is highly questionable whether firms would actually pass the money along to their workers, because it is the businesses that are on the hook for the taxes. If businesses pass the money on to their workers and then are forced to pay the taxes on Jan. 1, then it would be a messy affair to somehow go about clawing that money back from their workers. Moreover, even if businesses did pass the tax holiday funding along, it is doubtful that most households would spend the money, figuring that they would have to pay the money back 3 months later.

Thus, this gambit only works if Congress comes back and passes legislation that waives the payroll tax obligations for the four months. More importantly, it only works in real time if everyone believes now that Congress will do that over the next few months. Given that both Democrats and Republicans in Congress panned the idea of a payroll tax cut at the beginning of these negotiations, there is no reason for people to assume that.

I would offer one point on this executive order. Most of the commentary I have seen on this order, from both the press and from economists and analysts who should know better, is that it makes no sense to do this because it is the unemployed who need help, and a payroll tax cut only helps those who already have a job. This is simply a careless argument. Refer back to pt. 1 above. The government is already replacing lost wages for those who are unemployed. That is the help being offered specifically to the unemployed. The payroll tax executive order is an imperfect substitute for a second round of household rebate checks (which were sent to everyone, regardless of job status). Obviously, the President cannot unilaterally authorize another round of checks to households on his own, but he does have the authority to delay the payment of tax obligations (the same authority used to delay Tax Day to July 15), so that it is the point of this order. There are plenty of reasons to pan this executive order, but those making the “it doesn’t make sense to help those who already have jobs” argument are totally off-base.


  1. Student loan moratorium. The CARES Act gave borrowers a 6-month interruption of their monthly payments interest-free for federal student loans, which expires September 30. The executive order would extend the payment moratorium and zero interest until the end of the coronavirus crisis. To be clear, it only applies to federal student loans, not the old private loans with a federal guarantee. Most experts seem to believe that this is clearly illegal, but there is no plausible candidate to legally challenge the order. The only loser from this order would appear to be the federal government, so it is unclear who would bother to sue.

So, in my view there are two questions that we need to ask.


  1. If this is all there is, what is the economic impact? In my view, the extra unemployment benefits, as long as they last, will be plenty to keep consumers in good shape. A $400 per week bonus on unemployment benefits would still be offering wage replacement or better for a significant portion of the wage scale. Granted, President Trump would probably have to find a different honey pot to tap to keep the funds flowing through the election, but I would assume that the Administration is prepared to do so if necessary.

I suspect that cutting the size of the benefit will actually speed up the hiring recovery. Notwithstanding some politically-motivated, poorly-designed academic work that defies common sense, I have seen more than enough anecdotal evidence, including from the Fed, which is not exactly a bastion of conservative thinking, to be convinced that the generosity of benefits have encouraged many unemployed to politely decline when offered their job back (or a new job). If I am right, then this trimming of the benefits will be good for employment, though a marginal drag on consumption, AND it will limit the cost of the program, which would keep the money flowing longer.

The moratoria on evictions and student loans are likely to roughly keep the status quo in place. I am assuming that, for the most part, the payroll tax holiday would not be implemented by most businesses or spent by households, even if they get the money.

This leaves several key elements of what was generally assumed to be in a forthcoming package left on the sidelines. Both sides were on board for another round of rebate checks (which, as I have argued above, the payroll tax delay is a flawed attempt to replace). Both sides were on board for authorizing a second round of PPP loans for small businesses that can prove severe damage caused by the pandemic. Democrats and most Republicans agree that there should be some money for state and local governments. At a minimum, for example, it sounded like everyone was on board to provide at least $100 billion for education funding and money for various health costs (vaccine research, testing, etc.). So, there is no question that these executive orders are not a full substitute for a well-designed fiscal package. Even President Trump would presumably admit that. Nonetheless, unless the orders get challenged in court and struck down quickly, they will at least provide some portion of the benefits that have expired or will expire soon, enough to allow the economy to continue to climb out of the huge hold caused by the virus and the resulting lockdowns.


  1. Do the executive orders make an eventual deal more or less likely? As I indicated throughout these negotiations, the Democrats thought they held all of the leverage and were prepared to play hard ball throughout. When they took this hard line, I doubt that Speaker Pelosi and Sen. Schumer thought President Trump would go through with these legally-dubious executive orders, which, while they may not be legal, offer huge political upside to Trump and will be politically difficult for Democrats to challenge in court (“they are trying to take away your benefits”). This is a terrible way to run the government, but as a political gambit, the orders do shift the leverage back toward the middle, or maybe even in President Trump’s favor. Now, Democrats have an added incentive to do a deal, because otherwise these executive orders will set a precedent that future Presidents can go around Congress in a pinch.

Secretary Mnuchin was on CNBC this morning, and he was arguing that the two sides should pass what they agree on, specifically funding for schools and a second round of PPP loans (and I would add household rebate checks and maybe some extra money for state and local governments). Democrats never wanted a piecemeal solution, because so much of the $3 trillion plus that they were asking for was difficult to justify on a stand-alone basis as a direct response to the pandemic or as proportional to the immediate need. So far, neither side seems all that eager to rush back to the negotiating table, but I still believe that the two sides will ultimately strike some sort of a deal, though it may take most of August to get there. I would also opine that whatever deal is negotiated will have a significantly smaller total price tag than what Pelosi and Schumer thought they could get last week.

Stay tuned.





 

Member
Joined
Dec 13, 2007
Messages
13,685
Tokens
Getting into this...
A buddy of mine has given me this chance twice and I passed..
If anyone is interested PM me for details.


"Not sure how much you know about this class action suit but the company, Spectrum settlement recovery, has been very successful over seventeen years in buying and filing claims in the two Visa, MasterCard Class action suits. They are in the process of buying a claim for approximately $2.8M which has a very high upside and very low risk. I am guessing the minimum investment will be $100K. Our return on the first suit was 6X+. On the current suit we’ve already been paid 3X+ on an unrelated class action suit. The owners are as smart as anyone you’ll ever meet. The payout time frame is 2-4 years. If you’re interested you’ll have to sign an NDA which I will arrange.

Commit is 9 days funding roughly 30 days.

Sent from my iPad
 

Member
Joined
Apr 30, 2009
Messages
5,008
Tokens
I'm wondering why gheh would need investors after 2 successful litigations. They should be funded themselves.
 

Member
Joined
Dec 13, 2007
Messages
13,685
Tokens
It was an invitation more than anything...I don't think getting investors has been a problem at all.

MH is back from his trip...


new-jt-banner-newsletter.png

late
Global Market Comments
August 10, 2020
Fiat Lux
Featured Trade:(MARKET OUTLOOK FOR THE WEEK AHEAD, or GET READY FOR THE REVERSAL)
(INDU), (SPY), (TLT), (DIS), (BAC), (GLD)
mti-pos-74.jpg


The Market Outlook for the Week Ahead, or Get Ready for the Reversal

Epidemics ebb and flow.Every spike is followed by a retreat. The cycle continues until everyone has been exposed to the disease….or is dead.

Covid-19 has been on a tear for the last two months, doubling the number of US deaths to 162,000. An interim peak is just around the corner.

What happens when Covid takes a vacation? All existing trends in the financial markets will reverse. The big tech stocks will take a long-needed rest. Bonds will sell off. Gold will retest its recent breakout level at $1927. The US dollar will briefly get off the mat.

That means we are about to see a resurgence of “recovery” stocks, which have been ignored since June due to the declining probability of an economic resurgence as the “V” shaped recovery went out the window. Any break in the disease will bring a rally in this group. Those include hotels, casinos, movie theaters, restaurants, airlines, cruise lines….and banks.

Banks are far and away the quality play here. While other sectors may not see black ink for years, or may not survive at all, banks are making money right now.

Thanks to Dodd-Frank, the banks entered this crisis with less leverage and far stronger balance sheets than in 2008-2009. They will profit from falling bond prices, rising interest rates, waning defaults, and benefit mightily from generous government subsidies from multiple stimulus programs.

Institutions are underweight in banks, yet they are still at two-thirds of their January peak prices when the market leaders are 50% above old all-time highs.

If I am wrong and the next “recovery” rally takes weeks, or even months to start, they will continue to drift sideways. That makes them perfect candidates for short-dated option calls spreads. These make money whether the share goes up, sideways, or down small.

The campaign for a spectacular second-half performance has begun!

The U.S. Economy added jobs at a slower pace. US job growth weakened in July, with only 1.763 million people re-employed around the US as opposed to nearly 5 million in June, higher than estimates. The unemployment rate fell to 10.2% from 11.1% in June. At least 31.3 million people were receiving unemployment checks in mid-July.

Weekly Jobless Claims ticked down. The advance figure for seasonally adjusted initial claims was 1,186,000, a decrease of 249,000 from the previous week’s revised level. The report reflected the 20th straight week that new claims topped 1 million as the pandemic was the catalyst for a slew of firings. This number was the lowest since late March when the country saw an unprecedented explosion in requests for unemployment assistance.

The rehiring trend loses pace, indicating that virus infections slowed the economic recovery. Many states closed parts of their economies again and consumers remained cautious about spending. U.S. firms added just 167,000 jobs in July, payroll processor ADP said Wednesday, far below June’s gain of 4.3 million and May’s increase of 3.3 million. The economy still has 13 million fewer jobs than it did in February.

Congress is still unable to agree on a stimulus bill, with the $600 per week unemployment benefit ending. This is taking place while the virus rages through the mid-west and south. New Corona cases have exploded to 60,000 per day. Republicans want to cut the $600 per week excess benefit to $200, while the Democrats believe the $600 per week should be upheld.

A vaccine could hammer tech stocks, says Goldman Sachs, sparking a sell-off in bonds and rotation out of technology into cyclical stocks. The U.S. election and the evolution of the virus will be key drivers of the market. Approval of a vaccine could challenge market assumptions both about. This also could end with high-quality tech stocks having a massive correction.

Disney’s (DIS) digital subscriber base surged past 100 million. The company’s digital streaming segment was the sole bright spot for the company with Disney+ having 60.5 million paying customers as of Monday – up from 54.5 million on May 4. Disney also announced blockbuster feature Mulan in select markets as a $30 rental. I can’t wait to watch it.

The U.S. economy will recover to pre-pandemic levels by the end of 2021. Federal Reserve Vice Chairman Richard Clarida revealed that he expects the economy to grow in the third quarter. The health crisis hasn’t yet caused long-term damage to the U.S. economy, he said in an interview with CNBC, but the risks will grow the longer the pandemic lasts.

The 30-year fixed mortgage rate dropped to 3.14%. Mortgage rates have fallen faster than ever, and they've been remarkably willing to set record low after record low. Risk-adverse investors have been plowing their money into Treasury bonds (TLT) and government guaranteed mortgage backed securities, for safety.

Gold (GLD) to surpass $3,000 per ounce in 18 months, says Bank of America (BAC). Prices for gold futures for December delivery climbed to a record high above $2,000 per ounce. Retailers in malls and dealers in New York City’s Diamond District are swamped by orders due to the pandemic.

When we come out the other side of this, we will be perfectly poised to launch into my new American Golden Age, or the next Roaring Twenties. With interest rates still at zero, oil cheap, there will be no reason not to. The Dow Average will rise by 400% or more in the coming decade. The American coming out the other side of the pandemic will be far more efficient and profitable than the old.

My Global Trading Dispatch has been flatlining for the past two weeks while I have been on vacation. July finished at a red hot 7.93%, delivering a 2020 year to date of 28.63%. That takes my eleven-year average annualizede performance to a new all-time high of 36.05%. My 11-year total return has stretched to 384.54%.

The only number that counts for the market is the number of US Coronavirus cases and deaths, which you can find here.
On Monday, August 10 at 11:00 AM EST, July US Inflation Expectationsare published.
On Tuesday, August 11 at 6:00 AM EST, The NFIB Small Business Optimism Index for July is released.
On Wednesday, August 12, at 8:30 AM EST, the July US Inflation Rate is out. At 10:30 AM EST, the EIA Cushing Crude Oil Stocks are out.
On Thursday, August 13 at 8:30 AM EST, the Weekly Jobless Claims are published.
On Friday, August 14, at 10:00 AM EST, the University of Michigan Consumer Sentiment is printed. At 2:00 PM, the Bakers Hughes Rig Count is released.
As for me, I shall be recovering from the multiple cuts and bruises I suffered from my 50-mile hike with the Boy Scouts. Nothing major, that beset multiple other hikers we encountered along the way, for which I provided first aid.
I managed to bring back 16 scouts who finished the entire 50 miles in seven days, accomplishing a vertical climb of 6,300 feet. Only a Marine graduating from boot camp could accomplish such an endurance contest.

It was all worth it. Every morning, I wound up to a view taken from a Christmas calendar. My exertions lost me 20 pounds, thus tripling my wardrobe. And the bears mercifully left us and our food supply alone.

Stay healthy,

John Thomas
CEO & Publisher
The Diary of a Mad Hedge Fund Trader


1yr-aug10.png

11yr-aug10.png

indu-aug10.png

tlt-aug10.png

gld-aug10.png

uup-aug10.png

John-hiking-july-2020.png

john-and-jack-daniels.png
[h=2]Pouring Jack Daniels on an Open Wound[/h]​


Quote of the Day

“With valuations rising and fundamentals deteriorating we are in Looney Tunes Land here. The coyote is running in midair”, said a hedge fund friend of mine about current stock market conditions.
looney-tunes.png




 

Member
Joined
Dec 13, 2007
Messages
13,685
Tokens
Getting into this...
A buddy of mine has given me this chance twice and I passed..
If anyone is interested PM me for details.


"Not sure how much you know about this class action suit but the company, Spectrum settlement recovery, has been very successful over seventeen years in buying and filing claims in the two Visa, MasterCard Class action suits. They are in the process of buying a claim for approximately $2.8M which has a very high upside and very low risk. I am guessing the minimum investment will be $100K. Our return on the first suit was 6X+. On the current suit we’ve already been paid 3X+ on an unrelated class action suit. The owners are as smart as anyone you’ll ever meet. The payout time frame is 2-4 years. If you’re interested you’ll have to sign an NDA which I will arrange.

Commit is 9 days funding roughly 30 days.

Sent from my iPad



This Market is going to chop around for a bit.
I'm doing the above..I just spoke the the guy who I think is the smartest person I know., super low risk high return calls it the best investments he's ever made from a risk stand point.

Seems like a no brainer.
 

Member
Joined
Apr 30, 2009
Messages
5,008
Tokens
Was the min 100k?
 

Member
Joined
Dec 13, 2007
Messages
13,685
Tokens
100k.
Had to sign the NDA today.
It basically works off a 17 year old suit with Visa(7 Billion) and a pool of monies bought at 25 cents on the dollar in trenches ..very strange deal but it's about giving people who didn't know that they had money coming the ability receive that money sooner at a what I'd call an advantageous rate to the buyer of the part of that pool.
It's a small deal..2.8 million total in the fund for a pool of around 12 Million dollars.

I can't get anyone in unfortunately I found out today but I would if I could and might be able to in the future.

It's all wrapped up in this series of litigations

https://www.retailconsumerproductsl...e-mastercard-visa-interchange-fee-litigation/
 

Member
Joined
Dec 13, 2007
Messages
13,685
Tokens
Got to take a deep breath on SQQQ and try to stay with the persuasive though that the nasdaq is over bought in a large way.
Worst case is a reverse split..then the math gets ugly.
As far as China goes they've made the right moves with C19 the fundamentals in the Shanghai market makes more sense to me right now.
I got pushed around today in a big way with BABA Down 13 % today alone and depending on the rhetoric next week it could get worst.
I'd stress rhetoric... it's a gift if like BABA JD or Tencent long.
I'm sticking with my plan trying to say cool.

BABA up 6 bucks today

Hopefully there will be more Rhetoric forthcoming.
BABA 165 by next week without Rhetoric, with more "government" comment I'll buy more on any dip.
 

Member
Joined
Dec 13, 2007
Messages
13,685
Tokens
[FONT=&quot]BABA shareholders:Blackrock: 88,193,000 sharesVanguard: 65,926,00 sharesPrice T. Rowe: 64,313,00 sharesBaillie Gifford: 51,146,000 sharesState Street Corp: 37,975,000 sharesJP Morgan: 27,422,000 sharesUBS Asset Mgt: 26,708,000 sharesHSBC Holdings: 26,094,000 sharesCapital Research Global: 25,753,000 sharesTemasek Holdings: 24,122,000 shares.Conclusion: (1) BABA isn’t going anywhere....[/FONT]
 

Member
Joined
Dec 13, 2007
Messages
13,685
Tokens

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
The coronavirus crisis has "cast a long shadow" over crude demand, the IEA said in its latest oil market report, as it lowered its forecasts for the first time in several months. Due to ongoing weakness in the aviation and travel sectors, the agency sees global crude demand for 2020 at 91.1M barrels per day, down 140K bpd from a previous projection and reflecting a fall of 8.1M bpd Y/Y. The agency also revised down its 2021 global oil demand estimate by 240K barrels per day to 97.1M bpd. The report comes shortly after oil majors from BP (NYSE:BP) to Shell (RDS.A, RDS.B) reported historic losses in Q2 as lockdown measures led to an unparalleled shock for energy markets.
imp
imp
imp
imp
imp
imp
imp
imp
imp
imp
imp
imp
imp
imp
imp
imp
imp
imp
imp
imp
Individual Investors Should Be Rewarded For Their Loyalty
tiickertm_finallogo_primary_2clr_rgb.png
The companies you own want to reward you! TiiCKER makes it easy to discover shareholder perks you may qualify for based on your individual share ownership.Start earning perks at TiiCKER.COM»

Jobless claims due amid stimulus deadlock
U.S. stock index futures inched between gains and losses overnight following a steady August rally that pushed the S&P 500 to the cusp of fresh record high on Wednesday. Traders are eyeing the latest round of jobless claims this morning, which are expected to have declined for a second straight week to 1.12M (from 1.186M). That would be the lowest level in almost five months, but would also mark the 21st week in which claims have topped 1M. Regarding a coronavirus stimulus package, House Speaker Nancy Pelosi said Democratic leaders and the White House are still "miles apart."
U.S. consumer prices jump in July
After tanking in the first two months of the pandemic, the consumer price index came roaring back, posting a gain that was double what economists had been expecting. U.S. inflation picked up pace as consumer prices jumped 0.6% again in July, mirroring the June increase. It was driven up by new and used car prices, but falling oil and food prices kept a lid on gains. The news came as the U.S. budget deficit climbed to $2.81T in the first 10 months of the budget year, exceeding any on record.
On to the next bankrupt retailer
How are mall owners coping with the coronavirus crisis? They're looking to scoop up high-profile tenants. Fresh off a deal to buy Brooks Brothers out of bankruptcy for $325M (with Authentic Brands), Simon Property Group (NYSE:SPG), the largest U.S. mall owner, and Brookfield Property Partners (NASDAQ:BPY), another major shopping center player, entered advanced talks to purchase J.C. Penney's (OTCPK:JCPNQ) retail operations. Simon has also been exploring the possibility of turning over space left by ailing department stores like Penney into Amazon (NASDAQ:AMZN) distribution hubs.
Netflix premiere before Broadway debut
More Broadway shows are finding a home in the streaming world during the COVID-19 pandemic. "Diana," a musical based on the life of Princess Diana, will be released on Netflix (NASDAQ:NFLX) next year ahead of its rescheduled Broadway debut on May 25, 2021 (it had originally been slated for an official opening in March 2020). "Hamilton," the runaway Broadway hit, also began streaming on Disney+ earlier this summer, while "The Prom," a Tony Award-nominated musical that ran on Broadway in 2018-19, is being developed for Netflix.
Go deeper: Change in thinking due to the streaming revolution.
Concerns about WeChat ban
While Tencent (OTCPK:TCEHY) is playing down the recent moves by Washington, saying soon to be banned WeChat (for international users) and key revenue driver Weixin (for mainland Chinese customers) are two separate products, more action from the U.S. may be on the table. The executive orders against TikTok (BDNCE) and WeChat could be "broader" than just those two apps, according to Secretary of State Mike Pompeo, adding that "American data will not end up in the hands of an adversary like the Chinese Communist Party." If Apple (NASDAQ:AAPL) is forced to remove WeChat from its global app stores, iPhone annual shipments will decline 25% to 30%, TF International Securities analyst Kuo Ming-chi wrote in a research note.
Go deeper: Multinationals raise concerns with the White House.
Shifting supply chains
The recent trade war, which has spiraled into a tech war, has also seen a shakeup of the global supply chain. Hon Hai Precision Industry, a key supplier to Apple (AAPL) that is also known as Foxconn (OTC:FXCOF), is gradually adding more capacity outside of China. The proportion outside the country is now at 30%, up from 25% last June, and the ratio will increase as the company seeks to avoid escalating tariffs on Chinese-made goods headed to U.S. markets. "No matter if it's India, Southeast Asia or the Americas, there will be a manufacturing ecosystem in each," Chairman Young Liu told investors, saying that while China will still play a key role in Foxconn's manufacturing empire, the country’s "days as the world's factory are done."
Aircraft subsidy dispute continues
The U.S. is maintaining 15% tariffs on Airbus (OTCPK:EADSY) aircraft despite moves by the EU to resolve a 16-year-old dispute over billions of dollars of aircraft subsidies (some tariffs were also introduced on French jams and and German knives). U.S. Trade Representative Robert Lighthizer said the bloc had not taken actions necessary to come into compliance with WTO rulings, and it was not enough for Airbus to increase loan repayments to France and Spain. An escalation will likely come in the fall when the EU is expected to win WTO approval to level its own tariffs over subsidies to Boeing (NYSE:BA).

What else is happening...
Churchill Downs (NASDAQ:CHDN) posts safety plan for rescheduled Kentucky Derby.
General Motors (NYSE:GM) to continue ventilator production in Indiana.
More GM news... Goldman Sachs (NYSE:GS) vies for credit card business.
Facebook (NASDAQ:FB), Snap (NYSE:SNAP) reportedly held talks to buy TikTok rival Dubsmash.
Wednesday's Key Earnings
Cisco (NASDAQ:CSCO) -6.4% AH as downside guidance overshadowed earnings beat.
SmileDirectClub (NASDAQ:SDC) -4.9% AH weighed down by pandemic disruptions.
Lyft (NASDAQ:LYFT) -1% AH following revenue drop of 61%.
Vroom (NASDAQ:VRM) -18.9% AH giving weak Q3 revenue forecast.

Today's Markets
In Asia, Japan +1.8%. Hong Kong -0.1%. China flat. India -0.2%.
In Europe, at midday, London -0.9%. Paris -0.1%. Frankfurt -0.2%.
Futures at 6:20, Dow flat. S&P -0.1%. Nasdaq -0.1%. Crude -0.3% to $42.55. Gold -0.5% to $1939.60. Bitcoin -1.2% to $11382.
Ten-year Treasury Yield -2 bps tp 0.67%
Today's Economic Calendar
8:30 Initial Jobless Claims
8:30 Import/Export Prices
10:30 EIA Natural Gas Inventory
11:00 Fed's Bostic: "Equitable Solutions for the Future of Cities"
1:00 PM Results of $26B, 30-Year Note Auction
4:30 PM Money Supply
4:30 PM Fed Balance Sheet

Companies reporting earnings today »


 

Member
Joined
Dec 13, 2007
Messages
13,685
Tokens
Another thought when sifting through the news this AM.
Are two FANGs about to be chopped down by the Feds?



Concerns about WeChat ban

While Tencent (OTCPK:TCEHY) is playing down the recent moves by Washington, saying soon to be banned WeChat (for international users) and key revenue driver Weixin (for mainland Chinese customers) are two separate products, more action from the U.S. may be on the table. The executive orders against TikTok (BDNCE) and WeChat could be "broader" than just those two apps, according to Secretary of State Mike Pompeo, adding that "American data will not end up in the hands of an adversary like the Chinese Communist Party." If Apple (NASDAQ:AAPL) is forced to remove WeChat from its global app stores, iPhone annual shipments will decline 25% to 30%, TF International Securities analyst Kuo Ming-chi wrote in a research note.
Go deeper: Multinationals raise concerns with the White House.



Postmaster shorting Amazon stock.


https://www.rawstory.com/2020/08/tr...ing-cash-off-of-post-office-contracts-report/
 

Member
Joined
Feb 28, 2005
Messages
8,810
Tokens
As the S&P gets nearer and nearer to 3400, I decided to pull back a little. I sold about 60% of my S&P funds and a couple of growth stock mutual funds. I'm going to sit on the cash for a while (maybe until after the election?). I may keep buying SQQQ.

Bozzie, are there any other stocks/etf's (besides SQQQ) that I should look at for a downturn? I'm not expecting a big crash or anything, just a pull back...so I want to explore other options. Thanks!
 

Member
Joined
Dec 13, 2007
Messages
13,685
Tokens
What part of the market do you want to short the S&P CB?

SPDN..X1..lower risk with the x1

You crush it with the S&P funds..well done on taking profits CB.
 

Member
Joined
Dec 13, 2007
Messages
13,685
Tokens
As the S&P gets nearer and nearer to 3400, I decided to pull back a little. I sold about 60% of my S&P funds and a couple of growth stock mutual funds. I'm going to sit on the cash for a while (maybe until after the election?). I may keep buying SQQQ.

Bozzie, are there any other stocks/etf's (besides SQQQ) that I should look at for a downturn? I'm not expecting a big crash or anything, just a pull back...so I want to explore other options. Thanks!

Some think if it can pass 3400 it'll run to 3600..Based on technicals I don't totally understand.
 

Forum statistics

Threads
1,120,340
Messages
13,580,509
Members
100,966
Latest member
theredzone1
The RX is the sports betting industry's leading information portal for bonuses, picks, and sportsbook reviews. Find the best deals offered by a sportsbook in your state and browse our free picks section.FacebookTwitterInstagramContact Usforum@therx.com